NICE has reviewed this guidance and is planning to update MTG3 within a suitable clinical guideline. Readers of the current guidance should be aware that CardioQ-ODM has been superseded by CardioQ-ODM+ and that the analysis on costs and potential savings in the current guidance may be subject to local pathway changes. Further information is in the review proposal and review decision documents.
NICE has developed medical technology guidance on the CardioQ-ODM.
NICE medical technology guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
NICE has said that the CardioQ-ODM oesophageal doppler monitor can be used in people who are having major surgery or high-risk surgery. It can also be used in people having surgery who would otherwise be monitored with a more invasive method. Hospital teams may want to use the CardioQ-ODM oesophageal doppler monitor because the evidence shows that it reduces the use of central venous catheters, complications after surgery and the length of stay in hospital without increasing the need for readmission to hospital or repeat surgery.
The guidance was amended in May 2011 to clarify that the study by Gan et al. (2002) included patients having general surgery.
Next review: May 2020
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.